How to buy Graybug Vision stock (Graybug Vision)

Graybug Vision is a biotechnology & medical research business based in the US. Graybug Vision shares (GRAY) are listed on the NASDAQ and all prices are listed in US Dollars. Graybug Vision employs 8 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Graybug Vision stock

Buy Graybug Vision stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Graybug Vision stock price (NASDAQ: GRAY)

Use our graph to track the performance of GRAY stocks over time.

Graybug Vision shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$7.94
200-day moving average more info button	$3.30
Wall St. target price	$49.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-20.63

Is it a good time to buy Graybug Vision stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Graybug Vision financials

Gross profit TTM	$0
Return on assets TTM	-38.18%
Return on equity TTM	-70.51%
Profit margin	0%
Book value	$1.66
Market Capitalization more info button	$121 million

TTM: trailing 12 months

Graybug Vision share dividends

We're not expecting Graybug Vision to pay a dividend over the next 12 months.

You may also wish to consider:

Have Graybug Vision's shares ever split?

Graybug Vision's shares were split on a 1:14 basis on 19 March 2023 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Graybug Vision shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Graybug Vision shares which in turn could have impacted Graybug Vision's share price.

Graybug Vision share price volatility

Over the last 12 months, Graybug Vision's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Graybug Vision's is 1.1992. This would suggest that Graybug Vision's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Graybug Vision's beta into context you can compare it against those of similar companies.

• Kodiak Sciences (KOD.US): 2.251
• Regenxbio (RGNX.US): 1.232
• Kala Pharmaceuticals (KALA.US): -2.142

Graybug Vision overview

Graybug Vision, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc.

Frequently asked questions

null
What percentage of Graybug Vision is owned by insiders or institutions?
Currently 2.585% of Graybug Vision shares are held by insiders and 54.52% by institutions. How many people work for Graybug Vision?
Latest data suggests 8 work at Graybug Vision. When does the fiscal year end for Graybug Vision?
Graybug Vision's fiscal year ends in December. Where is Graybug Vision based?
Graybug Vision's address is: 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065 What is Graybug Vision's ISIN number?
Graybug Vision's international securities identification number is: US38942Q1031